IP Library › Granted Patent US 10,618,950
Granted Patent B2
US 10,618,950 · App. 13/722,348 · Granted Apr 14, 2020

Method and device for fast dissolution of solid protein composition

Inventors: Erez Ilan (Kibbutz Netzer Sereni, IL); Kfir Regev (Tel-Aviv, IL); Dana Leitman (Tel-Aviv, IL); Israel Nur (Moshav Timmorim, IL); Moti Meron (Herzliah, IL); John Goodman (Ann Arbor, MI)
Assignees: Omrix Biopharmaceuticals Ltd.; Ethicon, Inc.
C07K14/75A61M5/284B01F3/12B01F5/0685B01F13/0023B01F13/0052B01F15/0225B01F15/0258A61M5/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,618,950
App. No.
13/722,348
Granted
Apr 14, 2020
Kind
B2
Abstract

Provided are methods and devices for dissolving solid protein compositions, such as solid compositions comprising fibrinogen, in an aqueous solvent. The methods comprise use of a closed container containing a volume of solid fibrinogen composition and a head space wherein the pressure within the headspace is sub-atmospheric. Aqueous solvent is introduced into the container while maintain the sub-atmospheric pressure, and subsequent to addition of the solvent, the size of the headspace is decreased to bring the pressure to atmospheric pressure. The devices are suitable for use in the disclosed method.

Claims (19)

1. A method for dissolving a solid fibrinogen composition in an aqueous solvent while minimizing or avoiding the presence of foam, comprising:

i) providing a closed container containing: a volume of the solid fibrinogen composition and a head space, wherein the internal pressure within the headspace is a sub-atmospheric pressure being not more than 500 mBar;

ii) while maintaining the internal pressure in the headspace at the sub-atmospheric pressure, introducing into the container a volume of the aqueous solvent which is less than the volume of the solid fibrinogen composition to form a solution comprising at least 40 mg fibrinogen/ml, wherein the pressure in the headspace is maintained at the sub-atmospheric level after introducing the entire volume of the aqueous solvent into the container;

iii) subsequent to ii), decreasing the size of the headspace in the container by decreasing the internal volume of the container and without allowing entry of air into the container until the internal pressure in the headspace equals atmospheric pressure; and

iv) agitating the solution until the fibrinogen dissolves,

wherein the aqueous solvent is contained within a reservoir,

wherein the container and the reservoir are in mutual fluid communication,

wherein the agitating comprises repeatedly transferring the aqueous solvent between the container and the reservoir and

wherein the dissolving is carried out over a period of up to 90 sec.

2. The method according to claim 1 , wherein the solid fibrinogen composition is a lyophilized cake.

3. The method according to claim 1 , wherein the density of fibrinogen in the solid fibrinogen composition is in the range of from at least 5 to lower than 63 mg/cc.

4. The method according to claim 3 , wherein the density of fibrinogen is not more than 23 mg/cc.

5. The method according to claim 1 , wherein the fibrinogen concentration in the obtained solution is from 40 mg/ml to 120 mg/ml.

6. The method according to claim 1 , wherein the aqueous solvent is a degassed aqueous solvent.

7. The method according to claim 1 , wherein the internal pressure in the headspace in step i) is not more than 0.12 mBar.

8. The method according to claim 1 , when a time interval of at least 5 seconds is allowed to elapse between completion of step ii) and commencement of step iii).

9. The method according to claim 8 , wherein the time interval is at least 20 seconds.

10. The method according to claim 1 , further comprising incubating the solution in the container.

11. The method according to claim 10 , wherein the incubating is carried out for no longer than 2 minutes.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2016
From: OMRIX BIOPHARMACEUTICALS LTD.
To: ETHICON, INC.
Reel/Frame 037775/0943 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2013
From: ILAN, EREZ; REGEV, KFIR; LEITMAN, DANA; NUR, ISRAEL; MERON, MOTI; GOODMAN, JOHN
To: OMRIX BIOPHARMACEUTICALS LTD.
Reel/Frame 030412/0007 →
Priority Claims (2)
IL 217273 · Dec 29, 2011 · national
IL 221180 · Jul 30, 2012 · national
Continuity (3)
Provisional Application 61582524 · Jan 3, 2012
Provisional Application 61677048 · Jul 30, 2012
Related Publication 20130312868A1 · Nov 28, 2013